Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanomaMarine Rousset, Mathiéu Molimard, Stéphane Bouchet et al.|Clinica Chimica Acta|2017Cited by 36
An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patientsMarine Rousset, Mathiéu Molimard, Karine Titier et al.|Clinica Chimica Acta|2017Cited by 33